Treatment | Pharma Marketer

Dendreon Finally Gets Some Respect, Sort Of

Wednesday, July 28th, 2010

After three years of hype and hope over the Provenge prostate cancer vaccine, a study published in The New England Journal of Medicine may finally offer Dendreon some long-sought validation for its controversial treatment. Ironically, the results of the IMPACT study yielded nothing new, but by showing up in the prestigious journal, the findings may bolster confidence in Provenge.

Posted in: Regulatory | 0 Comments »

Read the full story

Five high-value biotech stocks to watch (Page 3)

Tuesday, July 27th, 2010

1. Poniard (PARD Market Outperform): We had predicted that the Phase III SPEAR trial of picoplatin in SCLC would be successful; we were wrong

Posted in: Pharma News | 0 Comments »

Read the full story

GlaxoSmithKline, Anthera Pharmaceuticals: Novel Treatments for Cardiovascular Disease

Sunday, July 25th, 2010

Jason Chew submits: The cardiovascular disease (CVD) market is worth approximately $100 billion today and makes up 12% of all global pharmaceutical sales. Unit sales of medicines for CVD are growing, but patent expirations for drugs such as Lipitor will hold revenues down. The advent of statins in the treatment of CVD was an incredible advance in the field, however, recent attempts to develop new products have been less successful

Posted in: Pharma News | 0 Comments »

Read the full story

DMC: Novartis’ drug safe but not effective in mid-study analysis

Friday, July 23rd, 2010

An independent data monitoring committee (DMC) has

Posted in: Pharma News | 0 Comments »

Read the full story

NuPathe plans to raise $75M with IPO

Thursday, July 22nd, 2010

Conshohocken, PA-based NuPathe, which is developing a transdermal patch version of the popular

Posted in: Pharma News | 0 Comments »

Read the full story

Lilly CEO: Pipeline to soften patent losses

Wednesday, July 21st, 2010

Eli Lilly ( NYSE: LLY )

Posted in: Pharma News | 0 Comments »

Read the full story

Three Trades on FDA, Clinical Trial Binary Events

Wednesday, July 21st, 2010

Mike Havrilla submits: Below are some Regulatory Catalyst Index updates for companies with recent FDA and clinical trial related news… Osiris Therapeutics (NASDAQ: OSIR ) announced this morning that Health Canada has completed its initial evaluation and issued a priority (180-day) review for PROCHYMAL (remestemcel-L) (mesenchymal stem cells for intravenous infusion), which is seeking approval as an adult stem cell therapy for for the treatment of graft vs.

Posted in: Pharma News, Regulatory | 0 Comments »

Read the full story

Actelion gets option to buy Trophos for up to $250M

Tuesday, July 20th, 2010

Switzerland’s Actelion has paid €10 million for an exclusive option to acquire France’s Trophos, a private development company whose lead drug, olesoxime, is

Posted in: Pharma News | 0 Comments »

Read the full story

Gilead Sciences: Time to Take Another Look

Saturday, July 17th, 2010

Bret Jensen submits: Company Overview : Gilead Sciences, Inc. (GILD), a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Truvada, Atripla, Viread, and Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat serious invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa that is used for the treatment of chronic angina; Vistide, an antiviral medication that targets cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems.

Posted in: Pharma News | 0 Comments »

Read the full story

Adolor cuts 30 jobs as Entereg sales falter

Friday, July 16th, 2010

Exton, PA-based Adolor is cutting 30 jobs, or about a third of its workforce, as it attempts to reduce cash burn levels. The developer had 114 employees at the end of 2009

Posted in: Pharma News | 0 Comments »

Read the full story